The oral MDM2/p53 antagonist BI 907828 elicited preliminary antitumor activity and had a manageable safety profile in patients with MDM2-amplified dedifferentiated liposarcoma.
Adding capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer, according to long-term results from the Heikki Joensuu, MD, of Helsinki University Hospital, and colleagues looked at 15-year overall survival data from the trial, in which 1,500 patients with early breast cancer were randomized to one of two treatments:Three cycles of docetaxel plus capecitabine followed by three cycles of cyclophosphamide, epirubicin, and capecitabineThree cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil The analysis, published in the , showed a 15-year survival rate of 77.6% in the patients who received capecitabine compared with 73.3% in the other treatment group (HR 0.81, 95% CI 0.66-0.99, P=0.037).